Cephalon Sales Force Expansion Funding Vehicle Dissolved In Wake Of Enron
Executive Summary
Cephalon's investment vehicle to fund expanded sales efforts for Provigil (modafinil) and Gabitril (tiagabine) has been dissolved due to investor skepticism following the collapse of Enron
You may also be interested in...
Provigil Revamped Marketing Campaign To Launch After FDA Cites Promotions
Cephalon plans to proceed with a new marketing program for Provigil (modafinil) in February after receiving a letter from FDA objecting to many of its current promotional materials for the narcolepsy drug
Cephalon Provigil Cost Of Goods To Decrease From 22% Of Sales To 7%
Cephalon expects to reduce its cost of goods associated with the narcolepsy drug Provigil from 22% of sales to 7% of sales following its acquisition of the French company Lafon
Forest Celexa On Pace To Exceed $300 Mil.; W-L Nearing Payments
Warner-Lambert expects to begin earning co-promotion income from its marketing efforts for Forest's Celexa (citalopram) in the next quarter.